Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Suspended × zimberelimab × Clear all

Phase

Status

Recruiting 2 Completed 2 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 2 S 1 (combination) 2 Magnetic Resonance Spectroscopy 2 Gemcitabine 2 Drug Therapy 2 Carboplatin 2 Bevacizumab 2 zimberelimab 1 tivozanib 1 titanium silicide 1 tisagenlecleucel 1 sotigalimab 1 selinexor 1 pimonidazole 1 palbociclib 1 imisopasem manganese 1 iberdomide 1 gusacitinib 1 gallium 68 PSMA-11 1 fludarabine 1 cabazitaxel 1 belantamab mafodotin 1 axicabtagene ciloleucel 1 atezolizumab 1 Testosterone Propionate 1 Testosterone 1 Temozolomide 1 TPI-287 1 Specimen Handling 1 Radiopharmaceuticals 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡